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Epithelial  ovarian cancer (OC) is the most lethal 
gynaecological malignancy worldwide with 22,530 estimated 
new cases in 2019, 13,980 deaths in 2019 and a median 
overall survival (OS) of less than 5 years (1). Indeed most 
of the cases are diagnosed in advanced stage and despite 
optimal management with a combination of surgery and 
platinum-base chemotherapy, most patients recur (2). The 
introduction of PARP inhibitors in treatment algorithms, 
has changed prognosis above all of BRCA mutated and 
homologous recombination deficient (HRD) positive patients 
but recurrence is still associated with development of drug 
resistance (and above all platinum resistance), low response 
rate to subsequent therapies and eventually death (2).
Among different therapeutic strategies one of the most 
appealing seems to be the use of immune modulating agents. 
Preclinical data suggest that immune microenvironment 
has a prognostic role also in OC. Presence of a high 
number of intratumor infiltrating lymphocytes (TILs) 
has been associated with a longer OS (3,4) and although 
OC has a low tumor mutational burden (TMB), it is well 
known that HRD positive patients, having an impaired 
mechanism of DNA repair, express a higher percentage of 
neoantigens (5). Indeed patients with both HRD and high 
CD3+ T lymphocytes have a longer OS if compared to 
HR proficient patients with low CD3+ T lymphocytes (6). 
On the other hand data on PDL-1 expression seems to be 
uncertain, indeed works described it both as a positive (7,8) 
and negative (9) prognostic factor.
In a context of limited therapeutic options for relapsed 
disease, several early phase studies evaluated the role 
of immune checkpoint inhibitors in OC patients. In 
Keynote-100 (10), a large II trial, 376 patients with 
recurrent OC have been treated with Pembrolizumab 
200 mg administered intravenously every 3 weeks. The 
study population was divided in two cohorts of patients: 
cohort A, including patients that received more than 1 and 
less than 3 prior lines with a platinum free interval (PFI) or 
treatment free interval (TF) (that is the time elapsed from 
last platinum-based cycle or last treatment respectively and 
evidence of disease progression) of 3–12 months and cohort 
B receiving four to six prior lines with a PFI or TFI longer 
than 3 months. Primary endpoint was overall response rate 
(ORR) per RECIST1.1 by blinded independent central 
review (BICR) in cohort A and B and by PDL-1 expression 
as described below (10).
The ORR in the overall population was 8.0% with 7.4% 
in cohort A, 9.9% in cohort B. Disease control rate (DCR) 
was about 37%. Median progression free survival (PFS) was 
2.1 months with a median OS not reached in cohort A and 
17.6 months in cohort B (10).
PDL-1 expression was defined with the PD-L1 IHC 
22C3 pharmDx assay, Dako North America using a 
combined positive score (CPS) that is “the number of PD-
L1 staining cells (tumor cells, lymphocytes, macrophages) divided 
by the total number of viable tumor cells” (10). In patients with 
CPS <1 ORR was 5.0% whereas it was 10.2% for CPS ≥1, 
and 17.1% for CPS ≥10 patients. No difference in HRD 
and BRCA status was shown between responders and non-
responders (10).
Results from Keynote-100 confirm the activity observed 
in Keynote-028, where patients with platinum resistant OC 
and PDL1 positivity, defined as PDL-1 expression in more 
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than 1% of cells in tumor, achieved an ORR of 11.5% with 
pembrolizumab (11). Moreover, these data are comparable 
to those from other early phase trials testing other immune 
checkpoint inhibitors like avelumab, nivolumab and 
atezolizumab in EOC (12-14).
Keynote-100 (10) is the largest published study with an 
anti-PD1 in OC patients. Interestingly, its primary endpoint 
was not only to evaluate activity of pembrolizumab but to 
define a cutoff in PDL-1 expression that could discriminate 
responders from non-responders. Apparently, also this 
endpoint was met, being outcome in PDL-1 better than 
patients with PDL1 low.
Nevertheless several question are still open. First of 
all, defined cutoff is highly dependent on the type of test, 
indeed studies in other cancers suggests that assays are 
not interchangeable and that they could miss some PDL-
1 high patients (15). Moreover role of PDL-1 depends 
on the type of cells with PDL-1 expression (cancer cells 
or immune cells) and there is a high temporal and spatial 
heterogeneity (16). Second, we cannot define if PDL-1 high 
is only prognostic or also predictive of a higher response 
specifically to immunotherapy. In other malignancies like 
non-small cell lung cancers (NSCLC), prognostic role of 
PDL-1 is not defined (17,18), but it is a good predictive 
biomarker both for pembrolizumab alone or in combination 
with chemotherapy in first line treatment (19-21). Also 
in cisplatin- ineligible patients with advanced urothelial 
cancer, a high expression of PDL-1 correlated with a better 
response to pembrolizumab (22). This led to FDA approval 
of pembrolizumab single agent in both malignancies only in 
patients with a high expression of PDL-1 (23).
Several other biomarkers could integrate PDL-1. Among 
these Mismatch repair deficiency (24), TMB that are 
indirect markers of high neoepitope production or T cell-
inflamed gene expression profile (GEP) that indicate an 
“inflamed” tumor microenvironment (25).
Once again, also combined biomarkers don’t fit with OC. 
A low percentage of OC patients has a high TMB and T-cell 
GEP or shows MMR deficiency (24,25), features that seem 
to predict a higher ORR and a longer OS with checkpoint 
inhibitors.
Therefore, even if Keynote-100 suggests that PDL-1 
could be a good predictive biomarker, ORR in patients with 
CPS >10 is comparable with single agent chemotherapy (2) 
and does not help in identifying subgroups of patients that 
might long term benefit from the use of pembrolizumab.
The core question is if we are missing the point. Is the 
problem the absence of a predictive biomarker or that 
this therapeutic strategy is not successful in OC patients. 
Indeed, in other malignancies, like melanoma, although a 
defined biomarker is still unavailable, results from several 
studies with long follow up suggest that immune checkpoint 
inhibitors guarantee a high response rate with a flat plateau 
of long responders at five years (26).
Data from early phase trials in OC patients, on the other 
hand, suggest that PD1/PD-L1 blockade is not enough 
powerful to achieve a clinically relevant response but 
several trials are evaluating different strategies to overcome 
immune tolerance.
An interesting approach is to combine immune 
checkpoint inhibitors with other agents that could enhance 
response. Among these, the most promising partners for 
immunotherapy seem to be PARP inhibitors (27). Indeed 
results from MEDIOLA study describe an ORR of more 
than 70% in platinum sensitive gBRCA mutated OC 
patients treated with durvalumab and olaparib, suggesting 
that probably both a selection of patients and a combination 
of treatments could improve outcome (27). Nevertheless 
patients with platinum resistant OC in TOPACIO study 
achieved an ORR of 18% with a combination of niraparib 
and pembrolizumab, results comparable to other standard 
treatment in this setting (27).
Other possible strategies under investigation to exploit 
tumor microenvironment are adoptive immune therapies (28). 
Indeed infusion of autologous or allogenic immune cells 
(for example TILs or engineered cells like CART) show 
promising results in preclinical settings and data from a 
phase I trial demonstrate that OC patients treated with 
TILs after surgery and cisplatin based therapy have an 
OS of 100% compared to 67.5% in patients treated with 
chemotherapy only (27).
Although results are preliminary and further data are 
needed, they give hope that also patients with OC could 
benefit from immunotherapy. In this context translational 
research is crucial to better understand immune system and 
successfully improve immune response against OC.
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